The survival rate of patients with beta-thalassemia major and intermedia and its trends in recent years in Iran
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
OBJECTIVES: Thalassemia is a common genetic disease in Iran, especially in the north and south of Iran. The present study sought to determine the survival rate of patients with thalassemia in highly endemic regions of Iran and its variation in patients born before and after 1971. METHODS: The present historical cohort study extracted data from the health records of patients with beta-thalassemia major, beta-thalassemia intermedia, and sickle beta-thalassemia who had presented to thalassemia treatment centers in the past years. The collected data were analyzed using the Kaplan-Meier test, the log-rank test, and the chi-square test. RESULTS: Of the total of 5,491 medical records (2,647 men and 2,634 women; mean age, 23.81±11.32 years), 3,936 belonged to patients with beta-thalassemia major, and 999 and 89 to patients with beta-thalassemia intermedia and sickle beta-thalassemia, respectively. In 467 cases, the type of thalassemia was not clear. The cumulative survival rate was calculated as 0.92, 0.83, 0.74, and 0.51 by ages 25, 35, 45, and 55, respectively. The hazard ratio of death was 4.22 (p<0.05) for beta-thalassemia major and 0.77 for beta-thalassemia intermedia (p=0.70). It was calculated as 1.45 for men patients and as 3.82 for single patients. CONCLUSIONS: The present study showed relatively high survival rates in patients with thalassemia. The survival of patients was unfavorable in poorer regions (Zahedan and Iranshahr). Factors including women gender, a higher level of education, being married, and living in metropolises decreased the risk of death at younger ages and improved survival.
Abstract
OBJECTIVES: Thalassemia is a common genetic disease in Iran, especially in the north and south of Iran. The present study sought to determine the survival rate of patients with thalassemia in highly endemic regions of Iran and its variation in patients born before and after 1971. METHODS: The present historical cohort study extracted data from the health records of patients with beta-thalassemia major, beta-thalassemia intermedia, and sickle beta-thalassemia who had presented to thalassemia treatment centers in the past years. The collected data were analyzed using the Kaplan-Meier test, the log-rank test, and the chi-square test. RESULTS: Of the total of 5,491 medical records (2,647 men and 2,634 women; mean age, 23.81±11.32 years), 3,936 belonged to patients with beta-thalassemia major, and 999 and 89 to patients with beta-thalassemia intermedia and sickle beta-thalassemia, respectively. In 467 cases, the type of thalassemia was not clear. The cumulative survival rate was calculated as 0.92, 0.83, 0.74, and 0.51 by ages 25, 35, 45, and 55, respectively. The hazard ratio of death was 4.22 (p<0.05) for beta-thalassemia major and 0.77 for beta-thalassemia intermedia (p=0.70). It was calculated as 1.45 for men patients and as 3.82 for single patients. CONCLUSIONS: The present study showed relatively high survival rates in patients with thalassemia. The survival of patients was unfavorable in poorer regions (Zahedan and Iranshahr). Factors including women gender, a higher level of education, being married, and living in metropolises decreased the risk of death at younger ages and improved survival.
참고문헌 (34)
- Aessopos A, "Cardiac involvement in thalassemia intermedia: a multicenter study", Blood, 97, pp.3411~3416 (2001)
- Olivieri NF, "The β-thalassemias", N Engl J Med, 341, pp.99~109 (1999)
- Haddad A, "β-thalassemia intermedia: a bird’s-eye view", Turk J Haematol, 31, pp.5~16 (2014)
- Rund D, "Beta-thalassemia", N Engl J Med, 353, pp.1135~1146 (2005)
- Borgna-Pignatti C, "Survival and complications in thalassemia", Ann N Y Acad Sci, 1054, pp.40~47 (2005)
- Borgna-Pignatti C, "Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine", Haematologica, 89, pp.1187~1193 (2004)
- Ladis V, "Longitudinal study of survival and causes of death in patients with thalassemia major in Greece", Ann N Y Acad Sci, 1054, pp.445~450 (2005)
- Zurlo MG, "Survival and causes of death in thalassaemia major", Lancet, 2, pp.27~30 (1989)
- Bazrgar M, "Causes for hospitalization and death in Iranian patients with β-thalassemia major", Pediatr Hematol Oncol, 28, pp.134~139 (2011)
- Borgna-Pignatti C, "Modern treatment of thalassaemia intermedia", Br J Haematol, 138, pp.291~304 (2007)
- Aessopos A, "Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia", Chest, 127, pp.1523~1530 (2005)
- Taher A, "Thalassemia intermedia: revisited", Blood Cells Mol Dis, 37, pp.12~20 (2006)
- Aessopos A, "Heart disease in thalassemia intermedia: a review of the underlying pathophysiology", Haematologica, 92, pp.658~665 (2007)
- Bannerman RM, "Thalassemia intermedia, with iron overload, cardiac failure, diabetes mellitus, hypopituitarism and porphyrinuria", Am J Med, 42, pp.476~486 (1967)
- Rafsanjani KA, "Complications of β-thalassemia intermedia in Iran during 1996–2010 (single-center study)", Pediatr Hematol Oncol, 28, pp.497~508 (2011)
- Haghpanah S, "Epidemiology of hemoglobinopathies and thalassemias in individuals referred to the haematology research centre, Shiraz University of Medical Sciences, Shiraz, Iran from 2006 to 2011", Hemoglobin, 38, pp.287~288 (2014)
- Habibzadeh F, "Thalassemia in Iran; an overview", Arch Iran Med, 1, pp.27~33 (1998)
- Saleh-Gohari N, "Distribution of β-globin gene mutations in thalassemia minor population of Kerman Province, Iran", Iran J Public Health, 39, pp.69~76 (2010)
- Vichinsky EP, "Changing patterns of thalassemia worldwide", Ann N Y Acad Sci, 1054, pp.18~24 (2005)
- Kosaryan M, "Survival of thalassemic patients referred to the Boo Ali Sina Teaching Hospital, Sari, Iran", Hemoglobin, 31, pp.453~462 (2007)
- Abolghasemi H, "Thalassemia in Iran: epidemiology, prevention, and management", J Pediatr Hematol Onc, 29, pp.233~238 (2007)
- Kazemnejad A, "Survival analysis of patients suffering from thalassemia in Hormozgan province", Modares J Med Sci (Pathobiol), 4, pp.173~180 (2002)
- Galanello R, "Beta-thalassemia", Orphanet J Rare Dis, 5, pp.11~ (2010)
- Joly P, "Beta-thalassemias: molecular, epidemiological, diagnostical and clinical aspects", Ann Biol Clin (Paris), 72, pp.639~668 (2014)
- Dixit A, "Hydroxyurea in thalassemia intermedia—a promising therapy", Ann Hematol, 84, pp.441~446 (2005)
- Borgna-Pignatti C, "Survival and disease complications in thalassemia major", Ann N Y Acad Sci, 850, pp.227~231 (1998)
- Khoei RA, "Survival analysis of patients with thalassemia major using parametric and semiparametric survival models", J Health Adm, 18, pp.82~91 (2015)
- Zamani R, "Survival analysis and its associated factors of beta thalassemia major in Hamadan province", Iran J Med Sci, 40, pp.233~239 (2015)
- Rajaeefard A, "Analysis of survival data in thalassemia patients in Shiraz, Iran", Epidemiol Health, 37, pp.e2015031~ (2015)
- Roudbari M, "The survival analysis of beta thalassemia major patients in South East of Iran", Saudi Med J, 29, pp.1031~1035 (2008)
- Brittenham GM, "Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major", N Engl J Med, 331, pp.567~573 (1994)
- Chern JP, "Survival, mortality, and complications in patients with beta-thalassemia major in northern Taiwan", Pediatr Blood Cancer, 48, pp.550~554 (2007)
- Latifi SM, "Survival analysis of β-thalassemia major patients Khouzestan province referring to Shafa hospital", Sci Med J, 9, pp.83~92 (2010)
- Modell B, "Survival and desferrioxamine in thalassaemia major", Br Med J (Clin Res Ed), 284, pp.1081~1084 (1982)